Journal
NATURAL PRODUCT RESEARCH
Volume 29, Issue 5, Pages 484-490Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/14786419.2014.951932
Keywords
combination; NF-kB; cell cycle; brucine; breast cancer; synergy; gemcitabine
Categories
Funding
- Sugen Life Sciences Pvt Ltd
Ask authors/readers for more resources
This study was designed to investigate the combination effects of brucine and gemcitabine, each with anticancer properties, in MCF-7 human breast cancer cells in culture. With regard to cell viability, effects of both the drugs and their combinations were inversely proportional to dose and time. For various proportional drug combinations studied, combination effects were analysed using CompuSyn software. The analyses revealed synergistic and/or additive effects regarding cell viability, anchorage-independent growth and cell migration. Combination analyses exhibited diversified impacts of the type of combination treatment, namely pretreatment with either drug followed by exposure to the other, or treatment with both drugs at the same time. Compared with untreated cells, combination treatment of asynchronised MCF-7 cells resulted in 17.2x decrease in G2 phase, increasing G1 (2.1x) and S (1.5x) phase cells in cell cycle analysis. Brucine, either individually or in combination, but not gemcitabine, inhibited NF-kB subunit (p65) expression in MCF-7 cells.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available